REVEFENACIN (has an active metabolite) | REVEFENACIN | ATC R03BB08
RESPIRATORY TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ANTICHOLINERGIC MUSCARINIC ANTAGONIST LEADING TO BRONCHODILATION | INHALATION | Cmax 0.26 NANOMOLAR Tmax 0.45 HOUR F 3 PERCENT (INHALATION COMPARED TO ORAL) VD 218 LITER PPB 71 PERCENT HT 46 HOUR SOLUBILITY SLIGHTLY SOLUBLE IN WATER | MUSCARINIC RECEPTORS M1 TO M5 | Muscarinic acetylcholine receptor M1 UNIPROT P11229 CHRM1 -- Muscarinic acetylcholine receptor M2 UNIPROT P08172 CHRM2 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |